Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

Clinical trial NCT07221942 · RECRUITING

Trial details

NCT number: NCT07221942
Sponsor: Fox Chase Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Urothelial Carcinoma Unresectable Urothelial Carcinoma Advanced Urothelial Carcinoma

Start date: 2026-01-23
Primary completion: 2028-09-01
Enrollment: 97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.